Advertisement

Annals of Surgical Oncology

, Volume 22, Issue 3, pp 780–786 | Cite as

Clinical Significance of Cytological Status of Peritoneal Lavage Fluid During Intraperitoneal Chemotherapy for Gastric Cancer with Overt Peritoneal Dissemination

  • Shigenobu Emoto
  • Joji Kitayama
  • Hironori Ishigami
  • Hironori Yamaguchi
  • Toshiaki Watanabe
Gastrointestinal Oncology

Abstract

Background

A positive cytology of peritoneal lavage fluid (CY1) is a poor prognostic factor in patients with gastric cancer (GC). We have recently reported that CY1 often changes to negative (CY0) following combination chemotherapy including intraperitoneal (IP) paclitaxel (PTX), which results in marked prolongation of survival in GC patients with peritoneal dissemination (P1).

Methods

A total of 95 P1 GC patients who received combination chemotherapy with S-1 and intravenous and IP PTX were enrolled. Peritoneal lavage fluid was periodically examined cytologically at the start of every cycle of chemotherapy, and the impact of CY status on patient outcome was retrospectively evaluated.

Results

Seventy-three (76.8 %) of 95 patients were diagnosed as CY1 before initial treatment. Median survival time (MST) of the CY1 group was significantly shorter than that of the CY0 group (19.1 vs. 32.5 months, P = 0.033). Cytological status changed from CY1 to CY0 in 68 (93.2 %) of 73 CY1 patients during the whole treatment period and MST of patients who showed a negative change was significantly longer than that of the unchanged group (20.0 vs. 13.0 months, P = 0.0017). In 64 patients who achieved CY0 by IP PTX regimen, the median time to achieve CY0 was 1.4 months, and patients who achieved a negative change within 1 month showed a particularly good outcome (MST = 26.1 months).

Conclusions

Periodic cytological examination of peritoneal lavage fluid is clinically useful to evaluate the efficacy of treatment as well as to predict the outcome of patients with P1 GC.

Keywords

Gastric Cancer Median Survival Time Peritoneal Metastasis Negative Change Cytological Examination 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Notes

Acknowledgment

This work was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Labor and Welfare of Japan, and by a grant-in-aid of the Public Trust Surgery Research Fund, Tokyo, Japan. We thank Ms. I. Nieda for her clerical work.

Funding

This work was funded by the Ministry of Education, Culture, Sports, Science and Technology of Japan and the Ministry of Health, Labor and Welfare of Japan, and by a grant-in-aid of the Public Trust Surgery Research Fund, Tokyo, Japan.

Disclosures

The authors have no financial disclosure.

References

  1. 1.
    Brigand C, Arvieux C, Gilly FN, Glehen O. Treatment of peritoneal carcinomatosis in gastric cancers. Dig Dis. 2004;22(4):366-73.PubMedCrossRefGoogle Scholar
  2. 2.
    Isobe Y, Nashimoto A, Akazawa K, et al. Gastric cancer treatment in Japan: 2008 annual report of the JGCA nationwide registry. Gastric Cancer. 2011;14(4):301-16.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Matharu G, Tucker O, Alderson D. Systematic review of intraperitoneal chemotherapy for gastric cancer. Br J Surg. 2011;98(9):1225-35.PubMedCrossRefGoogle Scholar
  4. 4.
    Yonemura Y, Elnemr A, Endou Y, et al. Effects of neoadjuvant intraperitoneal/systemic chemotherapy (bidirectional chemotherapy) for the treatment of patients with peritoneal metastasis from gastric cancer. Int J Surg Oncol. 2012;2012:148420.PubMedCentralPubMedGoogle Scholar
  5. 5.
    Coccolini F, Cotte E, Glehen O, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12-26.PubMedCrossRefGoogle Scholar
  6. 6.
    Kitayama J. Intraperitoneal chemotherapy against peritoneal carcinomatosis: Current status and future perspective. Surg Oncol. 27 2014;23(2):99–106.PubMedCrossRefGoogle Scholar
  7. 7.
    Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE. Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Ann Surg Oncol. 2010;17(12):3173-3180.PubMedCrossRefGoogle Scholar
  8. 8.
    La Torre M, Ferri M, Giovagnoli MR, et al. Peritoneal wash cytology in gastric carcinoma. Prognostic significance and therapeutic consequences. Eur J Surg Oncol. 2010;36(10):982-986.PubMedCrossRefGoogle Scholar
  9. 9.
    Lee SD, Ryu KW, Eom BW, Lee JH, Kook MC, Kim YW. Prognostic significance of peritoneal washing cytology in patients with gastric cancer. Br J Surg. 2012;99(3):397-403.PubMedCrossRefGoogle Scholar
  10. 10.
    Sobin LG. TNM classification of malignant tumours, 7th edn. New York: Wiley; 2009.Google Scholar
  11. 11.
    Association JGC. Japanese classification of gastric carcinoma, 3rd English edn. Gastric Cancer. 2011;14(2):101-12.CrossRefGoogle Scholar
  12. 12.
    Yonemura Y, Bandou E, Sawa T, et al. Neoadjuvant treatment of gastric cancer with peritoneal dissemination. Eur J Surg Oncol. 2006;32(6):661-5.PubMedCrossRefGoogle Scholar
  13. 13.
    Fushida S, Kinoshita J, Yagi Y, et al. Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: a feasibility and pharmacokinetic study. Oncol Rep. 2008;19(5):1305-10.PubMedGoogle Scholar
  14. 14.
    Yonemura Y, Endou Y, Shinbo M, et al. Safety and efficacy of bidirectional chemotherapy for treatment of patients with peritoneal dissemination from gastric cancer: Selection for cytoreductive surgery. J Surg Oncol. 2009;100(4):311-6.PubMedCrossRefGoogle Scholar
  15. 15.
    Ishigami H, Kitayama J, Kaisaki S, et al. Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67-70.PubMedCrossRefGoogle Scholar
  16. 16.
    Fujiwara Y, Takiguchi S, Nakajima K, et al. Neoadjuvant intraperitoneal and systemic chemotherapy for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol. 2011;18(13):3726-31.PubMedCrossRefGoogle Scholar
  17. 17.
    Fujiwara Y, Takiguchi S, Nakajima K, et al. Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination. J Surg Oncol. 2012;105(1):38-42.PubMedCrossRefGoogle Scholar
  18. 18.
    Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354-8.PubMedCrossRefGoogle Scholar
  19. 19.
    Lorenzen S, Panzram B, Rosenberg R, et al. Prognostic significance of free peritoneal tumor cells in the peritoneal cavity before and after neoadjuvant chemotherapy in patients with gastric carcinoma undergoing potentially curative resection. Ann Surg Oncol. 2010;17(10):2733-9.PubMedCrossRefGoogle Scholar
  20. 20.
    Japanese Gastric Cancer Association: Japanese Classification of Gastric Carcinoma—2nd English Edition. Gastric Cancer 1998;1:10–24.PubMedCrossRefGoogle Scholar
  21. 21.
    Ishigami H, Kitayama J, Otani K, et al. Phase I pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology. 2009;76(5):311-4.PubMedCrossRefGoogle Scholar
  22. 22.
    Emoto S, Ishigami H, Hidemura A, et al. Complications and management of an implanted intraperitoneal access port system for intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis. Jpn J Clin Oncol. 2012;42(11):1013-9.PubMedCrossRefGoogle Scholar
  23. 23.
    Kitayama J, Ishigami H, Yamaguchi H, et al. Salvage Gastrectomy After Intravenous and Intraperitoneal Paclitaxel (PTX) Administration with Oral S-1 for Peritoneal Dissemination of Advanced Gastric Cancer with Malignant Ascites. Ann Surg Oncol. 2014;21(2):539-46.PubMedCrossRefGoogle Scholar
  24. 24.
    Bang YJ, Kim YW, Yang HK, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet. 2012;379(9813):315-21.PubMedCrossRefGoogle Scholar
  25. 25.
    Katsuragi K, Yashiro M, Sawada T, Osaka H, Ohira M, Hirakawa K. Prognostic impact of PCR-based identification of isolated tumour cells in the peritoneal lavage fluid of gastric cancer patients who underwent a curative R0 resection. Br J Cancer. 2007;97(4):550-6.PubMedCentralPubMedCrossRefGoogle Scholar
  26. 26.
    Cotte E, Peyrat P, Piaton E, et al. Lack of prognostic significance of conventional peritoneal cytology in colorectal and gastric cancers: results of EVOCAPE 2 multicentre prospective study. Eur J Surg Oncol. 2013;39(7):707-14.PubMedCrossRefGoogle Scholar
  27. 27.
    Leake PA, Cardoso R, Seevaratnam R, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(Suppl 1):S27-37.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2014

Authors and Affiliations

  • Shigenobu Emoto
    • 1
  • Joji Kitayama
    • 1
  • Hironori Ishigami
    • 1
  • Hironori Yamaguchi
    • 1
  • Toshiaki Watanabe
    • 1
  1. 1.Department of Surgical OncologyThe University of TokyoBunkyo-kuJapan

Personalised recommendations